Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LILLY SUPPORTING SHAMAN’s RAIN FOREST RESEARCH WITH $4 MIL.

Executive Summary

LILLY SUPPORTING SHAMAN's RAIN FOREST RESEARCH WITH $4 MIL. equity investment and a four-year renewable R&D collaboration to discover and develop drugs to treat systemic fungal infections, the two firms announced Oct. 22. Shaman Pharmaceuticals will collect plant extracts found in tropical rain forests that exhibit antifungal activity and provide the initial screening to identify the most promising candidates; Lilly will conduct all the additional studies and have the option to acquire exclusive worldwide marketing rights to any developed products. Lilly is interested in developing broad-spectrum orally active agents to treat systemic fungal infections caused by candida, aspergillus and cryptococcus found in immunocompromised patients suffering from AIDS and the effects of chemotherapy or organ transplants, Shaman said. San Carlos, Calif.-based Shaman will retain rights to certain antifungals with limited applications in niche markets, including a topical agent now in late preclinical development. The $4 mil. equity investment will give Lilly a 6.5% stake in Shaman. Lilly is Shaman's first U.S. partner; the three-year-old firm's only other collaborator is Inverni della Beffa, an Italian pharmaceutical company. Shaman has two products in clinicals, which the firm is sponsoring without any corporate partners Provir, an oral antiviral for the treatment of respiratory viruses is in Phase I trials and a topical treatment for herpes is in Phase I/II clinicals. Shaman describes itself as a pharmaceutical company that combines "folk history, modern medicine, structured research and the tools of modern chemistry" to analyze plant extracts for their therapeutic potential and improve the efficiencies of the drug discovery process. In addition, it is committed to conserving the tropical ecosystem via a nonprofit organization, the Healing Forest Conservancy; Shaman will donate profits and royalties to the organization to help the countries in which it works preserve their natural resources. Shaman's research is conducted in all the countries in South America, southeast Asia and Africa that have tropical flora. The firm employs ethnobotanists to learn from "medicine men" or local healers (shaman) which plants are used to treat disease and infection. The local people are also used to collect the plants. Shaman has 36 full-time employees, including 16 MDs or PhDs. The startup was founded in 1989 by Lisa Conte who was previously a consultant for pharmaceutical companies.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel